Verve Therapeutics Incorporated developing a novel approach to the care of cardiovascular disease - transforming treatment from chronic management to single-course gene editing medicines. Verve's lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient's risk for cardiovascular disease. Verve Therapeutics was incorporated in 2018 and is headquartered in Cambridge, MA.
What is Verve Therapeutics's quote symbol?
What is the 52 week high and low for Verve Therapeutics (NASDAQ: VERV)?
How much is Verve Therapeutics stock worth today?
How much is Verve Therapeutics's stock price per share?
What is Verve Therapeutics's Market Cap?